Sequenom Shares Rise 11 Percent, Luminex Drops | GenomeWeb
Shares of Sequenom rose 11 percent for the four-day trading period ended Tuesday. Almost all of that increase came after Oppenheimer analyst Sean Lavin on Monday initiated the stock with a “buy” rating. Lavin put an $8 price target on Sequenom’s shares, which were trading at $5.20 on Wednesday afternoon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.